News & Events
13,000 data sets in EUMelaReg
We are pleased to announce that we have reached the enormous number of 13,000 data sets in the European Melanoma Registry. This is the result of the constant work and commitment of everyone involved i...
New member at EUMelaReg: Welcome North Macedonia
We are happy to welcome a new member on board: North Macedonia has joined the Central and South Eastern European Melanoma Expert Group (CSEEMEG), becoming the 17th country to join EUMelaReg. With its...
Second EUMelaReg poster at SMR congress 2023
We are proud that another EUMelaReg project was accepted for poster presentation at the SMR congress this year: “Efficacy of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 t...
EUMelaReg PD-SEQ poster presented at SMR congress 2023
An EUMelaReg real world evidence study with the title “Upfront usage of single agent anti-PD1 antibodies versus combined BRAF and MEK inhibitors in metastatic or unresectable BRAF V600 mutated melanom...
EUMelaReg website: new section "Publications"
We are pleased to inform you that we have set up a new "Publications" area on our website. This section offers an insight into EUMelaReg scientific projects and publications. The poster of the EUMelaR...
EUMelaReg ADJU-SEQ poster presented at ESMO congress 2023
As part of the EUMelaReg ADJU-SEQ project a subanalysis was performed and accepted for poster presentation at the ESMO Congress 2023 in Madrid (Abstract title: Efficacy of immune checkpoint inhibition...
EUMelaReg Annual Meeting in Madrid
This year, the Annual Meeting took place on the day before the ESMO Congress in Madrid and is now an established event at which EMR members exchange information. The meeting focus was on the presentat...
New member in the European Melanoma Registry: Welcome Albania
We are pleased to announce that another country has joined the European Melanoma Registry: we warmly welcome Albania on board. We look forward to sharing knowledge, experience and collaboration with o...
EUMelaReg PD-SEQ project accepted at SMR congress 2023
We are pleased to report that the EUMelaReg PD-SEQ project abstract has been accepted for poster presentation at the upcoming Society for Melanoma Research 20th International Congress 2023 in Philadel...
EUMelaReg ADJU-SEQ subanalysis accepted at ESMO congress 2023
As part of the EUMelaReg ADJU-SEQ project a subanalysis was performed and submitted as an abstract to the ESMO Congress. We are pleased to announce that this subanalysis has been accepted for poster p...
First patients documented in NMSC registry
After two successful online training sessions on documentation in the NMSC registry, we are glad to inform that the first patients have already been enrolled in the registry. Following this successful...
Patients with NMSC – a registry-based cohort study
EUMelaReg has started a registry-based cohort study and presented an e-poster at EADO 2023 on “Modern Treatment Usage and Outcome of Patients with Advanced Non-Melanoma Skin Cancer (NMSC) – a Registry...
EMR Project on acral lentiginous melanoma (ALM) at EADO 2023
At the EUMelaReg SDAC & IDC Retreat, a project was discussed, which was presented as an e-poster at the EADO congress: “Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibiti...
EUMelaReg Expert Reception at EADO 2023
GET-TOGETHER ON NMSC REGISTRY STUDY
Learn more about our European initiative with its new registry entities BCC and SCC and find out more about our study concept on advanced and high-risk NMSC patie...
EUMelaReg SDAC & IDC Retreat
At the end of February 2023, after months of online exchange, there was finally the opportunity for a face-to-face meeting again. The two EUMelaReg committees SDAC (Scientific and Data Access) and IDC...